Nevertheless, there are a few monoclonal antibodies, such as MEDI9447 (AstraZeneca), BMS-986179 (Bristol-Meyer Squibb), SRF373/NZV930, CPI-006/CPX-006, IPH5301, and TJ004309, which have entered Phase I/II clinical trials possessing antitumor activity against CD73 for the treatment of tumours in areas of the body such as the breast, pancreas, prostate, and lung [1,3]. This evidence concerns the gene NT5E and neoplasm.